These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17761416)

  • 21. Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases.
    Grolla AA; Podestà V; Chini MG; Di Micco S; Vallario A; Genazzani AA; Canonico PL; Bifulco G; Tron GC; Sorba G; Pirali T
    J Med Chem; 2009 May; 52(9):2776-85. PubMed ID: 19344175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors.
    Fréchette S; Leit S; Woo SH; Lapointe G; Jeannotte G; Moradei O; Paquin I; Bouchain G; Raeppel S; Gaudette F; Zhou N; Vaisburg A; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Robert MF; Lu A; Rahil J; Robert Macleod A; Besterman JM; Li Z; Delorme D
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1502-6. PubMed ID: 18207391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.
    Noronha G; Barrett K; Boccia A; Brodhag T; Cao J; Chow CP; Dneprovskaia E; Doukas J; Fine R; Gong X; Gritzen C; Gu H; Hanna E; Hood JD; Hu S; Kang X; Key J; Klebansky B; Kousba A; Li G; Lohse D; Mak CC; McPherson A; Palanki MS; Pathak VP; Renick J; Shi F; Soll R; Splittgerber U; Stoughton S; Tang S; Yee S; Zeng B; Zhao N; Zhu H
    Bioorg Med Chem Lett; 2007 Feb; 17(3):602-8. PubMed ID: 17113292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling.
    Chen YD; Jiang YJ; Zhou JW; Yu QS; You QD
    J Mol Graph Model; 2008 Apr; 26(7):1160-8. PubMed ID: 18061500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
    Pescatore G; Kinzel O; Attenni B; Cecchetti O; Fiore F; Fonsi M; Rowley M; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5528-32. PubMed ID: 18809328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha-mercaptoketone based histone deacetylase inhibitors.
    Wash PL; Hoffman TZ; Wiley BM; Bonnefous C; Smith ND; Sertic MS; Lawrence CM; Symons KT; Nguyen PM; Lustig KD; Guo X; Annable T; Noble SA; Hager JH; Hassig CA; Malecha JW
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6482-5. PubMed ID: 18954984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors.
    Manku S; Allan M; Nguyen N; Ajamian A; Rodrigue J; Therrien E; Wang J; Guo T; Rahil J; Petschner AJ; Nicolescu A; Lefebvre S; Li Z; Fournel M; Besterman JM; Déziel R; Wahhab A
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1866-70. PubMed ID: 19272776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization.
    Kattar SD; Surdi LM; Zabierek A; Methot JL; Middleton RE; Hughes B; Szewczak AA; Dahlberg WK; Kral AM; Ozerova N; Fleming JC; Wang H; Secrist P; Harsch A; Hamill JE; Cruz JC; Kenific CM; Chenard M; Miller TA; Berk SC; Tempest P
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1168-72. PubMed ID: 19138845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).
    Raeppel S; Zhou N; Gaudette F; Leit S; Paquin I; Larouche G; Moradei O; Fréchette S; Isakovic L; Delorme D; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; Wang J; Besterman JM; Murakami K; Li Z; Vaisburg A
    Bioorg Med Chem Lett; 2009 Feb; 19(3):644-9. PubMed ID: 19114304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
    Chen PC; Patil V; Guerrant W; Green P; Oyelere AK
    Bioorg Med Chem; 2008 May; 16(9):4839-53. PubMed ID: 18397827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
    Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N
    J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
    Lu A; Luo H; Shi M; Wu G; Yuan Y; Liu J; Tang F
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4924-7. PubMed ID: 21741834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
    Mahboobi S; Dove S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
    J Med Chem; 2009 Apr; 52(8):2265-79. PubMed ID: 19301902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors.
    Muraglia E; Altamura S; Branca D; Cecchetti O; Ferrigno F; Orsale MV; Palumbi MC; Rowley M; Scarpelli R; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6083-7. PubMed ID: 18930398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors.
    Kim HM; Hong SH; Kim MS; Lee CW; Kang JS; Lee K; Park SK; Han JW; Lee HY; Choi Y; Kwon HJ; Han G
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6234-8. PubMed ID: 17904843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors.
    Chen Y; He R; Chen Y; D'Annibale MA; Langley B; Kozikowski AP
    ChemMedChem; 2009 May; 4(5):842-52. PubMed ID: 19350613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
    Itoh Y; Suzuki T; Kouketsu A; Suzuki N; Maeda S; Yoshida M; Nakagawa H; Miyata N
    J Med Chem; 2007 Nov; 50(22):5425-38. PubMed ID: 17929798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives.
    Suzuki T; Ando T; Tsuchiya K; Fukazawa N; Saito A; Mariko Y; Yamashita T; Nakanishi O
    J Med Chem; 1999 Jul; 42(15):3001-3. PubMed ID: 10425110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
    Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
    J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors.
    Loudni L; Roche J; Potiron V; Clarhaut J; Bachmann C; Gesson JP; Tranoy-Opalinski I
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4819-23. PubMed ID: 17624773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.